More than 125 million people worldwide suffer from some form of psoriasis. If you’ve struggled with your skin health this ...

Roflumilast demonstrated effectiveness and safety in treating psoriasis, with added benefits for patients with comorbidities.

A consistent safety profile and sustained efficacy were observed in patients with moderate to severe plaque psoriasis.

AX-158 has achieved clinical validation through its phase 2a trial for the treatment of patients with mild to moderate plaque psoriasis, Artax Biopharma announced in a press release.

The latest FDA approval was based on the results of the ADVANCE trial, which showed that five times as many adults with mild to moderate plaque psoriasis receiving oral Otezla 30 mg twice daily ...

Now, six months into the NSW Pharmacy Dermatology Trial, pharmacists are now also appropriately trained to manage impetigo ...

about 80% to 90% of people with psoriasis have plaque psoriasis. Most psoriasis patients have mild or moderate forms of the disease. The former means less than 3% of the body surface area is ...

Sotyktu (deucravacitinib) is a brand-name oral tablet that’s prescribed for plaque psoriasis in certain adults ... who took Sotyktu in clinical trials: Mild side effects can occur with Sotyktu ...

One study found that pain was self-reported as a symptom in over 4 in 10 people with plaque psoriasis. For some others, the same immune system that causes plaque on your skin could instead inflame ...

Last December, it secured FDA approval for the treatment of adult patients with plaque psoriasis, regardless of the severity of their symptoms, making it an option for all the estimated eight ...